NSABP FB-14

NSABP FB-14

A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer

Protocol Chair: Leisha A. Evans, MD, PhD

Protocol Officer: Samuel Jacobs, MD

Patient Population:
Patients with advanced triple-negative breast cancer

Target Accrual: 29 patients

Status: Active, Not Recruiting

ClinicialTrials.gov Identifier: NCT04024800